-
Je něco špatně v tomto záznamu ?
A Short Communication: Lamotrigine Levels in Milk, Mothers, and Breastfed Infants During the First Postnatal Month
I. Kacirova, M. Grundmann, H. Brozmanova,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- antikonvulziva krev metabolismus terapeutické užití MeSH
- epilepsie krev farmakoterapie metabolismus MeSH
- kojení metody MeSH
- lamotrigin krev metabolismus terapeutické užití MeSH
- lidé MeSH
- mateřské mléko metabolismus MeSH
- matky MeSH
- novorozenec MeSH
- retrospektivní studie MeSH
- sérum chemie MeSH
- těhotenství MeSH
- Check Tag
- lidé MeSH
- novorozenec MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Lamotrigine has become the most frequently prescribed drug in the treatment of pregnant women with epilepsy. Although some relevant studies have found a wide milk/maternal serum as well as infant/maternal serum concentration ratio, different infant ages at the time of sampling and small number of patients preclude comparison. The aim of this study was to provide a consistent evaluation. METHODS: Data of 43 nursing women treated by lamotrigine were evaluated retrospectively. The authors followed the transport of lamotrigine during the first postnatal month from mothers to breastfed infants through maternal milk between the years 2002 and 2017. RESULTS: Lamotrigine concentrations varied from 1.1 to 14.9 mg/L in the maternal serum, from <0.66 to 9.1 mg/L in the milk and between <0.66 and 6.9 mg/L in the infant serum. The milk/maternal serum concentration ratio ranged from <0.18 to 0.74 and the infant/maternal serum concentration ratio measured between <0.15 and 0.74. Highly significant correlations were found between milk and maternal serum levels and between infant serum levels and milk, maternal serum levels, lamotrigine daily dose, and also maternal dose related to the body weight. CONCLUSIONS: The authors confirmed the wide range of the milk/maternal serum concentration ratio and the infant/maternal serum concentration ratio. Although the degree of lamotrigine exposure to the breastfed infants was smaller than during gestation, 16% of the infant serum levels measured were within the therapeutic range used for the general epileptic population. Lamotrigine concentration monitoring in breastfed infant, in our opinion, is the most relevant aspect for the analysis of actual lamotrigine exposure in infants, especially in those with clinical symptoms.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006619
- 003
- CZ-PrNML
- 005
- 20200525142502.0
- 007
- ta
- 008
- 200511s2019 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/FTD.0000000000000604 $2 doi
- 035 __
- $a (PubMed)30688868
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kacirova, Ivana $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava. Department of Clinical Pharmacology and Laboratory Diagnostics, University Hospital Ostrava, Ostrava, Czech Republic.
- 245 12
- $a A Short Communication: Lamotrigine Levels in Milk, Mothers, and Breastfed Infants During the First Postnatal Month / $c I. Kacirova, M. Grundmann, H. Brozmanova,
- 520 9_
- $a BACKGROUND: Lamotrigine has become the most frequently prescribed drug in the treatment of pregnant women with epilepsy. Although some relevant studies have found a wide milk/maternal serum as well as infant/maternal serum concentration ratio, different infant ages at the time of sampling and small number of patients preclude comparison. The aim of this study was to provide a consistent evaluation. METHODS: Data of 43 nursing women treated by lamotrigine were evaluated retrospectively. The authors followed the transport of lamotrigine during the first postnatal month from mothers to breastfed infants through maternal milk between the years 2002 and 2017. RESULTS: Lamotrigine concentrations varied from 1.1 to 14.9 mg/L in the maternal serum, from <0.66 to 9.1 mg/L in the milk and between <0.66 and 6.9 mg/L in the infant serum. The milk/maternal serum concentration ratio ranged from <0.18 to 0.74 and the infant/maternal serum concentration ratio measured between <0.15 and 0.74. Highly significant correlations were found between milk and maternal serum levels and between infant serum levels and milk, maternal serum levels, lamotrigine daily dose, and also maternal dose related to the body weight. CONCLUSIONS: The authors confirmed the wide range of the milk/maternal serum concentration ratio and the infant/maternal serum concentration ratio. Although the degree of lamotrigine exposure to the breastfed infants was smaller than during gestation, 16% of the infant serum levels measured were within the therapeutic range used for the general epileptic population. Lamotrigine concentration monitoring in breastfed infant, in our opinion, is the most relevant aspect for the analysis of actual lamotrigine exposure in infants, especially in those with clinical symptoms.
- 650 _2
- $a antikonvulziva $x krev $x metabolismus $x terapeutické užití $7 D000927
- 650 _2
- $a kojení $x metody $7 D001942
- 650 _2
- $a epilepsie $x krev $x farmakoterapie $x metabolismus $7 D004827
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a lamotrigin $x krev $x metabolismus $x terapeutické užití $7 D000077213
- 650 _2
- $a mateřské mléko $x metabolismus $7 D008895
- 650 _2
- $a matky $7 D009035
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a sérum $x chemie $7 D044967
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Grundmann, Milan $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava.
- 700 1_
- $a Brozmanova, Hana $u Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava. Department of Clinical Pharmacology and Laboratory Diagnostics, University Hospital Ostrava, Ostrava, Czech Republic.
- 773 0_
- $w MED00004503 $t Therapeutic drug monitoring $x 1536-3694 $g Roč. 41, č. 3 (2019), s. 401-404
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30688868 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200525142501 $b ABA008
- 999 __
- $a ok $b bmc $g 1525477 $s 1096675
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 41 $c 3 $d 401-404 $e - $i 1536-3694 $m Therapeutic drug monitoring $n Ther Drug Monit $x MED00004503
- LZP __
- $a Pubmed-20200511